Biotech’s ‘distracted boyfriend’ is $3 billion richer. His fellow investors are still waiting for their share
Vivek Ramaswamy, the hedge fund manager turned biotech entrepreneur, was so confident he could make money from pharma drug castoffs, he named his new venture Roivant Sciences — the “Roi” being shorthand for return on investment.
Turns out, Ramaswamy meant his return on investment. Outside investors in Ramaswamy’s publicly traded “Vant” spinoffs are still waiting for their share.
